Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
Cabaletta Bio's 40% sell-off leaves CABA below its $2.41 pipeline value ahead of pivotal rese-cel autoimmune data in 2027, despite dilution…
Cypriot Invests NASDAQ
Cabaletta Bio, Inc.
CABA
1 story
$303M Market cap · 2026-10-12
Cypriot Invests 